Laura J Rojas1,2,3, Madiha Salim4, Eric Cober5, Sandra S Richter6, Federico Perez3,7, Robert A Salata7, Robert C Kalayjian8, Richard R Watkins9,10, Steve Marshall3, Susan D Rudin1,3, T Nicholas Domitrovic1,3, Andrea M Hujer1,3, Kristine M Hujer1,3, Yohei Doi11, Keith S Kaye4, Scott Evans12, Vance G Fowler13,14, Robert A Bonomo1,2,3,7,15, David van Duin16. 1. Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. 2. Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. 3. Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA. 4. Division of Infectious Diseases, Detroit Medical Center, Wayne State University, Michigan, USA. 5. Department of Infectious Diseases, Cleveland Clinic, Cleveland, Ohio, USA. 6. Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH, USA. 7. Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. 8. Department of Medicine, MetroHealth Medical Center, Cleveland, Ohio, USA. 9. Department of Internal Medicine, Northeast Ohio Medical University, Rootstown, OH , USA. 10. Division of Infectious Diseases, Cleveland Clinic Akron General Medical Center , Akron , OH , USA. 11. Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pennsylvania, USA. 12. Department of Biostatistics and the Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts, USA. 13. Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA. 14. Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA. 15. Departments of Pharmacology, Molecular Biology and Microbiology, Biochemistry, and Proteomics and Bioinformatics, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. 16. Division of Infectious Diseases, University of North Carolina, Chapel Hill, USA.
Abstract
Background: Polymyxins including colistin are an important "last-line" treatment for infections caused by carbapenem-resistant Klebsiella pneumoniae (CRKp). Increasing use of colistin has led to resistance to this cationic antimicrobial peptide. Methods: A cohort nested within the Consortium on Resistance against Carbapenems in Klebsiella pneumoniae (CRACKLE) was constructed of patients with infection, or colonization with CRKp isolates tested for colistin susceptibility during the study period of December, 2011 to October, 2014. Reference colistin resistance determination as performed by broth macrodilution was compared to results from clinical microbiology laboratories (Etest) and to polymyxin resistance testing. Each patient was included once, at the time of their first colistin-tested CRKp positive culture. Time to 30-day in-hospital all-cause mortality was evaluated by Kaplan-Meier curves and Cox proportional hazard modeling. Results: In 246 patients with CRKp, 13% possessed ColR CRKp. ColR was underestimated by Etest (very major error rate = 35%, major error rate = 0.4%). A variety of rep-PCR strain types were encountered in both the ColS and the ColR groups. Carbapenem resistance was mediated primarily by blaKPC-2 (46%) and blaKPC-3 (50%). ColR was associated with increased hazard for in-hospital mortality (aHR 3.48; 95% confidence interval, 1.73-6.57; P < .001). The plasmid-associated ColR genes, mcr-1 and mcr-2 were not detected in any of the ColR CRKp. Conclusions: In this cohort, 13% of patients with CRKp presented with ColR CRKp. The apparent polyclonal nature of the isolates suggests de novo emergence of ColR in this cohort as the primary factor driving ColR. Importantly, mortality was increased in patients with ColR isolates.
Background: Polymyxins including colistin are an important "last-line" treatment for infections caused by carbapenem-resistant Klebsiella pneumoniae (CRKp). Increasing use of colistin has led to resistance to this cationic antimicrobial peptide. Methods: A cohort nested within the Consortium on Resistance against Carbapenems in Klebsiella pneumoniae (CRACKLE) was constructed of patients with infection, or colonization with CRKp isolates tested for colistin susceptibility during the study period of December, 2011 to October, 2014. Reference colistin resistance determination as performed by broth macrodilution was compared to results from clinical microbiology laboratories (Etest) and to polymyxin resistance testing. Each patient was included once, at the time of their first colistin-tested CRKp positive culture. Time to 30-day in-hospital all-cause mortality was evaluated by Kaplan-Meier curves and Cox proportional hazard modeling. Results: In 246 patients with CRKp, 13% possessed ColR CRKp. ColR was underestimated by Etest (very major error rate = 35%, major error rate = 0.4%). A variety of rep-PCR strain types were encountered in both the ColS and the ColR groups. Carbapenem resistance was mediated primarily by blaKPC-2 (46%) and blaKPC-3 (50%). ColR was associated with increased hazard for in-hospital mortality (aHR 3.48; 95% confidence interval, 1.73-6.57; P < .001). The plasmid-associated ColR genes, mcr-1 and mcr-2 were not detected in any of the ColR CRKp. Conclusions: In this cohort, 13% of patients with CRKp presented with ColR CRKp. The apparent polyclonal nature of the isolates suggests de novo emergence of ColR in this cohort as the primary factor driving ColR. Importantly, mortality was increased in patients with ColR isolates.
Authors: D R Giacobbe; V Del Bono; E M Trecarichi; F G De Rosa; M Giannella; M Bassetti; A Bartoloni; A R Losito; S Corcione; M Bartoletti; E Mantengoli; C Saffioti; N Pagani; S Tedeschi; T Spanu; G M Rossolini; A Marchese; S Ambretti; R Cauda; P Viale; C Viscoli; M Tumbarello Journal: Clin Microbiol Infect Date: 2015-08-14 Impact factor: 8.067
Authors: Fred C Tenover; Portia P Williams; Sheila Stocker; Angela Thompson; Leigh Ann Clark; Brandi Limbago; Roberta B Carey; Susan M Poppe; Dean Shinabarger; John E McGowan Journal: J Clin Microbiol Date: 2007-07-18 Impact factor: 5.948
Authors: David van Duin; Eric Cober; Sandra S Richter; Federico Perez; Robert C Kalayjian; Robert A Salata; Scott Evans; Vance G Fowler; Robert A Bonomo; Keith S Kaye Journal: Infect Control Hosp Epidemiol Date: 2015-05-20 Impact factor: 3.254
Authors: David van Duin; Federico Perez; Susan D Rudin; Eric Cober; Jennifer Hanrahan; Julie Ziegler; Raymond Webber; Jacqueline Fox; Pamela Mason; Sandra S Richter; Marianne Cline; Geraldine S Hall; Keith S Kaye; Michael R Jacobs; Robert C Kalayjian; Robert A Salata; Julia A Segre; Sean Conlan; Scott Evans; Vance G Fowler; Robert A Bonomo Journal: Antimicrob Agents Chemother Date: 2014-05-05 Impact factor: 5.191
Authors: David van Duin; Eric Cober; Sandra S Richter; Federico Perez; Robert C Kalayjian; Robert A Salata; Scott Evans; Vance G Fowler; Keith S Kaye; Robert A Bonomo Journal: J Antimicrob Chemother Date: 2014-12-09 Impact factor: 5.790
Authors: Andrea Endimiani; Andrea M Hujer; Federico Perez; Christopher R Bethel; Kristine M Hujer; Jennifer Kroeger; Margret Oethinger; David L Paterson; Mark D Adams; Michael R Jacobs; Daniel J Diekema; Gerri S Hall; Stephen G Jenkins; Louis B Rice; Fred C Tenover; Robert A Bonomo Journal: J Antimicrob Chemother Date: 2009-01-20 Impact factor: 5.790
Authors: Joseph D Lutgring; Anny Kim; Davina Campbell; Maria Karlsson; Allison C Brown; Eileen M Burd Journal: J Clin Microbiol Date: 2019-04-26 Impact factor: 5.948
Authors: Anubhav Kanwar; Steven H Marshall; Federico Perez; Myreen Tomas; Michael R Jacobs; Andrea M Hujer; T Nicholas Domitrovic; Susan D Rudin; Laura J Rojas; Barry N Kreiswirth; Liang Chen; Miguel Quinones-Mateu; David van Duin; Robert A Bonomo Journal: Open Forum Infect Dis Date: 2018-04-23 Impact factor: 3.835